Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7219MR)

This product GTTS-WQ7219MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7219MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12063MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ2069MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ1623MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ3826MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ3526MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BART
GTTS-WQ4041MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI 655066
GTTS-WQ14380MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ4305MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIIB-054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW